Alkermes (ALKS) Price Target Increased After Narcolepsy Drug Data

Needham has raised the price target for Alkermes (ALKS) following positive data on its narcolepsy drug. The new target reflects optimism surrounding the drug's performance and its potential market impact. The stock's performance may see changes based on analysts' expectations, particularly in the context of treatment advancements for narcolepsy. Increased investor interest can affect trading volumes as news circulates about this pivotal milestone.